Advertisement

FDA grants Orphan Drug Designation to iadademstat in SCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Advertisement
Advertisement